Compare Expensify Inc (EXFY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Novo Nordisk A/S — how do they compare? Expensify Inc trades at $2.27 (market cap $209.73M), while Novo Nordisk A/S trades at $46.4 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 991× Expensify Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Expensify Inc pays none. Which is the better fit depends on your goals.
| EXFY | NVO | |
|---|---|---|
Market Cap | $209.73M | $207.85B |
Sector | Technology | Health |
52-Week High | $2.69 | $63.98 |
52-Week Low | $0.75 | $35.29 |
Enterprise Value | $149.35M | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.22, down 10.12% in the past 24 hours, with a bullish technical signal from moving averages and a neutral RSI. Recent Q2 2026 earnings showed a beat on EPS and a return to non-GAAP profitability, with revenue of $33.9 million. The company is expanding its AI-native solutions and European card offerings, supported by positive cash flow trends.
Outlook is cautiously optimistic due to earnings improvements and strategic expansions, but risks include persistent net losses, high P/E ratio of 258.82, and competitive pressures in expense management software. Analyst consensus is mixed with 44% buy ratings.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
